Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The Slovenia-based firm will use the funds to develop its Health Intelligence platform, expand into Asian markets, and open an office in the UK.
With $93M in new funding, large-scale storage vendor Qumulo is making a deeper push into life sciences, supporting research and clinical genomics alike.
Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.
Benchmark led a new investment round in digital lab notebook maker Benchling, which claims 500 percent year-over-year growth in annual recurring revenue.
Backed by Andreessen Horowitz and Polaris Partners, Camp4 hopes its high-resolution gene maps can shorten and remove risk from the drug development process.
Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.
With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.
The company said it would use the funding to continue development of its human microbiome research kits, protocols, and software.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.